TY - JOUR T1 - Existence of SARS-CoV-2 RNA on ambient particulate matter samples: A nationwide study in Turkey JF - medRxiv DO - 10.1101/2021.01.24.21250391 SP - 2021.01.24.21250391 AU - Özgecan Kayalar AU - Akif Arı AU - Gizem Babuscu AU - Nur Konyalılar AU - Özlem Doğan AU - Füsun Can AU - Ülkü A. Şahin AU - Eftade O. Gaga AU - S. Levent Kuzu AU - Pelin E. Arı AU - Mustafa Odabası AU - Yücel Taşdemir AU - S.Sıddık Cindoruk AU - Fatma Esen AU - Egemen Sakın AU - Burak Çalışkan AU - Lokman H. Tecer AU - Merve Fıçıcı AU - Ahmet Altın AU - Burcu Onat AU - Coşkun Ayvaz AU - Burcu Uzun AU - Arslan Saral AU - Tuncay Döğeroğlu AU - Semra Malkoç AU - Özlem Ö. Üzmez AU - Fatma Kunt AU - Senar Aydın AU - Melik Kara AU - Barış Yaman AU - Güray Doğan AU - Bihter Olgun AU - Ebru N. Dokumacı AU - Gülen Güllü AU - Elif S. Uzunpınar AU - Hasan Bayram Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/25/2021.01.24.21250391.abstract N2 - Coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 virus and has been affecting the world since the end of 2019. Turkey is severely affected with the first case being reported on March 11th 2020. Ambient particulate matter (PM) samples in various size ranges were collected from 13 sites including urban and urban background locations and hospital gardens in 10 cities across Turkey between the 13th of May and the 14th of June, 2020 to investigate a possible presence of SARS-CoV-2 RNA on ambient PM. A total of 155 daily samples (TSP, n=80; PM2.5, n=33; PM2.5-10, n=23; PM10, n=19; and 6 size segregated, n=48) were collected using various samplers in each city. The N1 gene and RdRP gene expressions were analyzed for the presence of SARS-CoV-2 as suggested by the Centers for Disease Control and Prevention (CDC). According to RT-PCR and 3D-RT-PCR analysis, dual RdRP and N1 gene positivity were detected in 20 (9.8 %) of the samples. The highest percentage of virus detection on PM samples was from hospital gardens in Tekirdağ, Zonguldak, and İstanbul—especially in PM2.5 mode. Samples collected from two urban sites were also positive. Findings of this study have suggested that SARS-CoV-2 may be transported by ambient particles especially at sites close to the infection hot-spots. However, whether this has an impact on the spread of the virus infection remains to be determined.Significance Statement Although there are several studies reporting the existence of SARS-CoV-2 in indoor aerosols is established, it remains unclear whether the virus is transported by ambient atmospheric particles. The presence of the SARS-CoV-2 RNA in ambient particles collected from characteristic sites within various size ranges was investigated, and positive results were found in urban sites especially around Turkish hospitals. In this context, this study offers a new discussion on the transmission of the virus via ambient particles.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors thank Koc University Research Center for Translational Medicine (KUTTAM) for funding the laboratory analysis of SARS-CoV-2 in PM samples. The authors thank to officials of Zonguldak Bulent Ecevit University Science and Technology Research Center, and Health Medical Research and Application Center for device support and workforce support during the sampling studies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:It is a work that does not require ethical permission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript can be available citing the manuscript. ER -